Corpus overview


Overview

MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    displaying 1 - 10 records in total 11
    records per page




    The Age Again in The Eye of The Covid-19 MESHD Storm: Evidence-Based Decision Making.

    Authors: M. Carmen Martín; Aurora Jurado; Cristina Abad-Molina; Antonio Orduña; Oscar Yarce; Ana M. Navas; Vanesa Cunill; Danilo Escobar; Francisco Boix; Sergio Burillo-Sanz; María C. Vegas-Sánchez; Yesenia Jiménez-de las Pozas; Josefa Melero; Marta Aguilar; Oana Irina Sobieschi; Marcos López-Hoyos; Gonzalo Ocejo-Vinyals; David San Segundo; Delia Almeida; Silvia Medina; Luis Fernández-Pereira; Esther Vergara; Bibiana Quirant; Eva Martínez-Cáceres; Marc Boigues; Marta Alonso; Laura Esparcia-Pinedo; Celia López-Sanz; Javier Muñoz-Vico; Serafín López-Palmero; Antonio Trujillo; Paula Álvarez; Álvaro Prada; David Monzón; Jesús Ontañón; Francisco M. Marco; Sergio Mora; Ricardo Rojo; Gema González-Martínez; María T. Martínez-Saavedra; Juana Gil-Herrera; Sergi Cantenys-Molina; Manuel Hernández; Janire Perurena-Prieto; Beatriz Rodríguez-Bayona; Alba Martínez; Esther Ocaña; Juan Molina

    doi:10.21203/rs.3.rs-228480/v1 Date: 2021-02-10 Source: ResearchSquare

    Background: One hundred million of contagions, more than 2 million deaths and less than one year of COVID-19 MESHD have changed our lives and our health management systems forever. Ageing is known to be one of the significant determinants for COVID-19 MESHD severity. Two main reasons underlie this: immunosenescence and age correlation with main COVID-19 MESHD comorbidities such as hypertension or dyslipidaemia MESHD. This study has two aims. The first is to obtain cut-off points for laboratory parameters that can help us in clinical decision-making. The second one is to analyse the effect of pandemic lockdown on epidemiological, clinical, and laboratory parameters concerning the severity of the COVID-19 MESHD. For these purposes, 257 of SARSCoV2 inpatients during pandemic confinement were included in this study. Moreover, 584 case records from a previously analysed series, were compared with the present study data. Results: Concerning the characteristics of lockdown series, mild cases accounted for 14.4%, 54.1% were moderate and 31.5%, severe. There were 32.5% of home contagions, 26.3% community transmissions, 22.5% nursing home contagions, and 8.8% corresponding to frontline worker contagions regarding epidemiological features. Age >60 and male sex are hereby confirmed as severity determinants. Equally, higher severity was significantly associated with higher IL6 HGNC, CRP HGNC, ferritin, LDH, and leukocyte counts, and a lower percentage of lymphocyte, CD4 HGNC and CD8 HGNC count. Comparing this cohort with a previous 584-cases series, mild cases were less than those analysed in the first moment of the pandemic and dyslipidaemia became more frequent than before. Age, lymphocyte count and LDH had similar distributions at both moments. IL-6 HGNC, CRP HGNC and LDH values above 69 pg/mL, 97 mg/L and 328 U/L respectively, as well as a CD4 HGNC T-cell count below 535 cells/μL, were the best cut-offs predicting severity since these parameters offered reliable areas under the curve. Conclusion: Age, sex and dyslipidaemia together with selected laboratory parameters on admission can help us predict COVID-19 MESHD severity and, therefore, make clinical and resource management decisions. Demographic features associated with lockdown could affect the homogeneity of the data and the robustness of the results.

    Universal health care access for all residents reduce mortality in COVID-19 MESHD patients in Abu Dhabi, UAE: A retrospective multicenter cohort study

    Authors: Nawal Al kaabi; Asma Al Nuaimi; Mariam Al Harbi; Jehad Abdalla; Tehmina Khan; Huda Gasmelseed; Asad Khan; Osama Hamdoun; Stefan Weber

    doi:10.21203/rs.3.rs-87753/v1 Date: 2020-10-04 Source: ResearchSquare

    Background: SARS‐CoV‐2 was first reported in December 2019. The severity of COVID-19 MESHD infection ranges from being asymptomatic to severe infection leading to death. The aim of the study is to describe the clinical characteristics and outcomes of hospitalized COVID-19 MESHD patients within the largest government healthcare facilities in the Emirate of Abu Dhabi, the capital of UAE. Methods:  This paper is a retrospective cross-sectional study of all patients admitted to Abu Dhabi Healthcare services facilities (SEHA) between the period of March 1 HGNCst until May 31st with a laboratory-confirmed test of SARS-CoV2, known as Coronavirus disease MESHD ( COVID19 MESHD). Variation in characteristics, comorbidities, laboratory values, length of hospital stay, treatment received and outcomes were examined. Data was collected from electronic health records available at SEHA health information system.Results: There were 9390 patients included; patients were divided into severe and non-severe groups. 721 (7.68%) patients required intensive care while the remaining majority (92.32 %) were mild-moderate cases. The mean age (41.8 years) is less than the mean age reported globally. Our population had a male predominance and variable representation of different nationalities. Three major comorbidities were noted, hypertension MESHD, diabetes mellitus MESHD and chronic kidney disease MESHD. The laboratory tests that were significantly different between the severe and the non-severe groups were LDH, Ferritin, CRP HGNC, neutrophil count, IL6 HGNC and creatinine level. The major antiviral therapies the patients have received were a combination of hydroxychloroquine and favipiravir. The overall in hospital mortality was 1.63% while severe group mortality rate was 19.56 %. The Death rate in the adults younger than 30 years was noted to be higher compared to elderly patients above 60 years, 2.3% and 0.9 % respectively. Conclusion: our analysis suggests that Abu Dhabi had a relatively low morbidity and mortality rate and a high recovery rate compared to published rates in China, Italy and The United States. The demographic of the population is younger and has an international representation. The country had the highest testing rate in relation to the population volume. We believe the early identification and younger demographic had affected the favorable comparative outcome in general with early identification of cases leading to a lower mortality rate. 

    More severe hypercoagulation status, cytokine storm, and disease progression in coronavirus disease 2019 MESHD with persistent RT-PCR negative results: a multicenter prospective study

    Authors: Wei Du; Guochao Shi; Min Zhou; Yahui Liu; Gelei Lan; Xueqing Du; Chunrong Huang; Ranran Dai; Wei Chen

    doi:10.21203/rs.3.rs-85866/v1 Date: 2020-09-30 Source: ResearchSquare

    Purpose: Persistent negative results (at least 3 times) of reverse transcription–polymerase chain reaction (RT-PCR) from pharyngeal swabs are not rare in coronavirus disease 2019 MESHD ( COVID-19 MESHD) patients, but their characteristics have not yet been well studied.Methods: PCR confirmed, serum antibody confirmed with persistent negative PCR results, and clinically diagnosed patients hospitalized in two medical centers during February and March 2020 were included. Differences in clinical, imaging and laboratory characteristics as well as factors affecting their prognosis were analyzed.Results: There were 114 PCR confirmed, 17 serology confirmed and 21 clinically diagnosed patients included. Time from onset of disease to the first PCR and admission were similar among the groups. Compared with PCR-confirmed patients, serology-confirmed patients were older and likely to have hypertension MESHD, vomiting MESHD, or symptoms of chest pain MESHD and dyspnea MESHD. Regarding imaging manifestations, serology-confirmed patients were more prone to pleural effusion MESHD. In addition, higher levels of C-reactive protein HGNC, neutrophil-to-lymphocyte ratio, total bilirubin, D-dimer, fibrinogen HGNC, troponin, interleukin-6 HGNC and IL-8 HGNC were also found. Although with similar mortality, serology confirmed patients were more likely to have disease progression. High levels of D-dimer and IL-6 HGNC were possibly the underlying factors leading to their worse prognosis. On the other hand, clinically diagnosed patients were more similar to PCR-confirmed patients.Conclusion: Serology confirmed COVID-19 MESHD patients with at least three negative PCR results had different clinical characteristics and were likely to have disease progression, possibly due to more severe hypercoagulation status MESHD and cytokine storm.

    A Comprehensive Evaluation of Early Predictors of Disease Progression in Patients with COVID-19 MESHD: A Case Control Study

    Authors: Qiang Tang; Yanwei Liu; Yingfeng Fu; Ziyang Di; Kailiang Xu; Bo Tang; Hui Wu; Maojun Di

    doi:10.21203/rs.3.rs-50527/v1 Date: 2020-07-29 Source: ResearchSquare

    Background: The 2019 coronavirus disease MESHD ( COVID-19 MESHD) has become an unprecedented public health crisis with nearly 16 million confirmed cases and 630,000 deaths worldwide. Methods: We retrospectively investigated the demographic, clinical, laboratory, radiological and treatment data of COVID-19 MESHD patients consecutively enrolled from January 18 to May 15, 2020, in Taihe and Jinzhou central hospital. Results: Of all 197 patients, the median age was 66.5 years (IQR 7-76), and 120 (60.9%) patients were males. We identified 88 (44.7%) of 197 COVID-19 MESHD patients as the disease progression (aggravation) cases. The aggravation cases tend to have more medical comorbidity: hypertension MESHD (34.1%), diabetes MESHD (30.7%), and presented with dyspnea MESHD (34.1%), neutrophilia (60.2%), and lymphocytopenia MESHD (73.9%), compared with those without. And the patients with disease progression showed significantly higher level of Fibrinogen HGNC (Fbg), D-dimer, IL-6 HGNC, C-reactive protein HGNC ( CRP HGNC), procalcitonin (PCT), and serum ferritin, and were more prone to develop organ damage in the liver, kidney, and heart (P<0.05). Multivariable regression showed that advanced age, comorbidities, lymphopenia MESHD, and elevated level of Fbg, lactate dehydrogenase (LDH), Cardiac troponin ( CTnI HGNC), IL-6 HGNC, serum ferritin were the significant predictors of disease progression. Further, we investigated antibody responses to SARS-CoV-2 and found that the levels of IgM and IgG were significantly higher in the disease progression cases compared to non-progression cases from 3 weeks after symptom onset. In addition, the disease progression group tended to peak later and has a more vigorous IgM/IgG response against SARS-CoV-2. Further, we performed Kaplan-Meier analysis and found that 61.6% of patients had not experienced ICU transfer or survival from hospital within 25 days from admission.Conclusions: Investigating the potential factors of advanced age, comorbidities and elevated level of IL-6 HGNC, serum ferritin and Kaplan-Meier analysis enables early identification and management of patients with poor prognosis. Detection of the dynamic antibody may offer vital clinical information during the course of SARS-CoV-2 and provide prognostic value for patients infection.  

    Comparative Survival Analysis of Immunomodulatory Therapy for COVID-19 MESHD 'Cytokine Storm': A Retrospective Observational Cohort Study

    Authors: Sonali Narain; Dimitre Stefanov; Alice S Chau; Andrew G Weber; Galina S Marder; Blanka Kaplan; Prashant Malhotra; Ona Bloom; Audrey Liu; Martin Lesser; Negin Hajizadeh

    doi:10.1101/2020.06.16.20126714 Date: 2020-06-19 Source: medRxiv

    BackgroundCytokine storm is a marker of COVID-19 MESHD illness severity and increased mortality. Immunomodulatory treatments have been repurposed to improve mortality outcomes. MethodsWe conducted a retrospective analysis of electronic health records across the Northwell Health system. COVID-19 MESHD patients hospitalized between March 1, 2020 and April 15, 2020, were included. Cytokine storm was defined by inflammatory markers: ferritin >700ng/mL, C-reactive protein HGNC >30mg/dL, or lactate dehydrogenase >300U/L. Patients were subdivided into six groups -no immunomodulatory treatment (standard of care) and five groups that received either corticosteroids, anti- interleukin 6 HGNC ( IL-6 HGNC) antibody (tocilizumab) or anti- IL-1 HGNC therapy (anakinra) alone or in combination with corticosteroids. The primary outcome was hospital mortality. ResultsThere were 3,098 patients who met inclusion criteria. The most common comorbidities were hypertension MESHD (40-56%), diabetes MESHD (32-43%) and cardiovascular disease MESHD (2-15%). Patients most frequently met criteria with high lactate dehydrogenase (74.8%) alone, or in combination, followed by ferritin (71.4%) and C-reactive protein HGNC (9.4%). More than 80% of patients had an elevated D-dimer. Patients treated with a combination of tocilizumab and corticosteroids (Hazard Ratio [HR]: 0.459, 95% Confidence Interval [CI]: 0.295-0.714; p<0.0001) or corticosteroids alone (HR: 0.696, 95% CI: 0.512-0.946; p=0.01) had improved hospital survival compared to standard of care. Corticosteroids and tocilizumab was associated with increased survival when compared to corticosteroids and anakinra (HR: 0.612, 95% CI: 0.391-0.958; p-value=0.02). ConclusionsWhen compared to standard of care, corticosteroid and tocilizumab used in combination, or corticosteroids alone, was associated with reduced hospital mortality for patients with COVID-19 MESHD cytokine storm.

    The Association Between Biomarkers and Clinical Outcomes in Novel Coronavirus ( COVID-19 MESHD) Pneumonia in a U.S. Cohort

    Authors: Shant Ayanian; Juan A Reyes; Lei Lynn; Karolyn Teufel

    doi:10.1101/2020.05.27.20115105 Date: 2020-05-29 Source: medRxiv

    Background: The global pandemic caused by COVID-19 MESHD remains poorly understood by clinicians. Identifying biologic markers associated with prognosis can help clinicians recognize disease severity. Objective: To describe the association between D-dimer, CRP HGNC, IL-6 HGNC, ferritin, LDH, and clinical outcomes in a cohort of COVID-19 MESHD patients treated on the inpatient medical service at a university hospital in Washington, DC. Design: In this retrospective study, we included all adults admitted to the inpatient medicine service at George Washington University Hospital between March 12, 2020 and May 9, 2020 with laboratory confirmed COVID-19 MESHD. Clinical and laboratory data were extracted from electronic medical records and compared between survivors not requiring ICU transfer, survivors requiring ICU transfer, survivors requiring intubation, and non-survivors. Key Results: 299 patients were included in our study, of whom 69 required transfer to the ICU, 39 required intubation, and 71 died. Threshold values for IL-6 HGNC (>50 pg/mL), D-dimer (>3 mcg/mL), ferritin (>450 ng/mL), CRP HGNC (>100 mg/L), and LDH (1,200 u/L) were found to be statistically significant and independently associated with higher odd of clinical deterioration and death. Hypertension MESHD, CVA and heart disease MESHD independently had an increased risk of all three outcomes, while CKD had only an increased risk of death MESHD. Patient co-morbidities had no effect on the different biomarkers' significant association with poor patient clinical outcomes, except cancer MESHD. Conclusion: Laboratory markers of inflammation MESHD and coagulopathy MESHD can help clinicians identify patients who are at high risk for clinical deterioration, independent of clinically significant medical comorbidities

    Clinical Features of Hypertensive Patients With Covid-19 MESHD Compared With a Normotensive Group

    Authors: shuang wang; qiang zhang; zhao bin zheng; peng wang; hua hong ye; xiao qing jing; jun hua zhang; da yu fan; ping jia; zhong dan zhang; ting ting luo; shi sheng zhu

    doi:10.21203/rs.3.rs-31685/v1 Date: 2020-05-26 Source: ResearchSquare

    Background: The novel coronavirus ( COVID-19 MESHD), which began in Wuhan, China, in December 2019, has spread worldwide and poses a great threat to human health. Among COVID-19 MESHD patients, those with hypertension MESHD have been reported to have higher morbidity and mortality. This study was conducted to provide the international community with a deeper understanding of COVID-19 MESHD with hypertension MESHD.Methods: A total of 188 COVID-19 MESHD patients were studied from January to March 2020. The epidemiology, clinical features, and laboratory data of hypertensive MESHD patients with COVID-19 MESHD were collected, retrospectively analyzed, and compared with a normotensive group. The use of anti- hypertensive MESHD drugs, general treatment, and clinical outcomes of hypertensive MESHD patients were also analyzed.Results: The median ages in hypertensive MESHD patients with mild and severe COVID-19 MESHD were both significantly greater than the median age in the normotensive group. But there was no significant gender difference between the hypertensive MESHD and normotensive groups. All patients had lived in the Wuhan area. Common symptoms of all of the patients included fever MESHD, cough MESHD, and fatigue MESHD. Chest CT scans showed bilateral patchy shadows or ground glass opacity in the lungs of all of the patients. All (98 [100%]) of the hypertensive MESHD patients received antiviral therapy (Arbidol was used alone or in combination with Ribavirin), antibiotic therapy (85 [86.7%]), and corticosteroids (31 [31.6%]). It has been suggested that the combination of Arbidol and Ribavirin as initial therapy for hypertensive MESHD patients with COVID-19 MESHD is effective and safe. There were no significant differences in laboratory data between the mild cases in the hypertensive MESHD and the normotensive groups. In the severe cases, the hypertensive MESHD patients had higher plasma levels of D-dimer, C-reactive protein HGNC ( CRP HGNC), and Interleukin-6 HGNC ( IL-6 HGNC) (P < 0.05). Furthermore, the hypertensive MESHD patients who were treated with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB) had no statistically significant differences between the mild and severe groups (p > 0.05).Conclusion: In this study, we demonstrated that the hypertensive MESHD patients who were treated with ACEI/ARB did not have an increased risk of developing severe COVID-19 MESHD. Arbidol and Ribavirin played an important role in the treatment of the viral pneumonia MESHD. Hypertensive MESHD patients with severe viral pneumonia MESHD had stronger inflammatory responses than non- hypertensive MESHD patients.

    COVID-19 MESHD in Spain: age, Interleukin-6 HGNC, C Reactive Protein HGNC and lymphocytes as key clues from a multicentre retrospective study

    Authors: Aurora Jurado; M Carmen Martin; Cristina Abad-Molina; Antonio Orduna; Alba Martinez; Esther Ocana; Oscar Yarce; Ana M Navas; Antonio Trujillo; Luis Fernandez-Pereira; Esther Vergara; Beatriz Rodriguez; Bibiana Quirant; Eva Martinez-Caceres; Manuel Hernandez; Janire Perurena; Juana Gil; Sergi Cantenys; Gema Gonzalez-Martinez; Maria Teresa Martinez-Saavedra; Ricardo Rojo; Francisco M Marco; Sergio Mora; Jesus Ontanon; Marcos Lopez-Hoyos; Gonzalo Ocejo-Vinyals; Josefa Melero; Marta Aguilar; Delia Almeida; Silvia Medina; Maria Carmen Vegas; Yesenia Jimenez; Alvaro Prada; David Monzon; Francisco Boix; Vanesa Cunil; Juan Molina

    doi:10.1101/2020.05.13.20101345 Date: 2020-05-16 Source: medRxiv

    Background. SARS-CoV-2 infection MESHD has widely spread to the hugest public health challenge to date, COVID-19 MESHD COVID-19 MESHD pandemic. Different fatality rates among countries are probably due to non-standardized records being carried out by local health authorities. Spanish case-fatality rate is 11.94%, far higher to those reported in Asia or by other European countries. A multicenter retrospective study was performed of demographic, clinical, laboratory and immunological features of 574 Spanish COVID-19 MESHD hospitalized patients and their outcomes. The use of use of renin HGNC-angiotensin system blockers was also analyzed as a risk factor. Results. In this study, 27.7% of cases presented a mild curse, 42% a moderate one and for 30.3% of cases, the course was severe. Ages ranged from 18 to 98 (average 63.2). Fifty eight percent (58.9%) of patients were male. Interleukin 6 HGNC was higher as severity increased. On the other hand, CD8 HGNC lymphocyte count was significantly lower as severity grew and subpopulations CD4 HGNC, CD8 HGNC, CD19 HGNC and NK showed concordant lowering trends. Severity-related natural killer percent descents were evidenced just within aged cases. A significant severity-related decrease of CD4 HGNC lymphocytes was found in males. The use of renin HGNC-angiotensin system blockers was associated with moderate or mild disease courses. Conclusions. Age and age-related comorbidities, such as dyslipidaemia, hypertension MESHD or diabetes MESHD, determined more frequent severe forms of the disease in this study than in previous literature cohorts. Our cases are older than those so far reported and clinical course of the disease is found to be impaired by age. Immunosenescence might be therefore a suitable explanation for immune system effectors severity-related hampering. Adaptive immunity would go exhausted and a huge ineffective and almost deleterious innate response would account for COVID-19 MESHD severity. Renin HGNC-angiotensin system blockers treatment in hypertensive MESHD patients has a protective effect as regarding COVID-19 MESHD severity.

    The characteristics and death risk factors of 132 COVID-19 MESHD pneumonia patients with comorbidities: a retrospective single center analysis in Wuhan, China

    Authors: Chen Chen; Zhang Jing Yi; Li Chang; Hu Zhi Shuo; Zhang Ming; Tu Pei; Liu Lei; Zong Wen Xia

    doi:10.1101/2020.05.07.20092882 Date: 2020-05-12 Source: medRxiv

    Background: The new coronavirus pneumonia MESHD ( COVID-19 MESHD) has evolved into a global pandemic disease, and the epidemiological characteristics of the disease have been reported in detail. However, many patients with new coronary pneumonia MESHD have comorbidities, and there are few researches reported in this special population. Methods: a retrospective analysis was performed on 132 consecutive COVID-19 MESHD patients with comorbidities from January 19, 2020 to March 7, 2020 in Hubei NO.3 People Hospital. Patients were divided into mild group and critical group and were followed up to the clinical endpoint. The observation biomarkers include the clinical feature, blood routine, blood biochemistry, inflammation MESHD biomarkers, and coagulation function. Univariate and multivariate logistic regression was used to analyze the risk factors associated with death MESHD. Results: 132 patients were enrolled in this study and divided into the mild group (n=109, 82.6%) and critical group (n=23, 17.4%), of whom 119 were discharged and 13 were died in hospital. The all-cause mortality rate was 9.8%, of which 7 patients died of respiratory failure MESHD, 5 patients died of heart failure MESHD, and 1 patient died of chronic renal failure MESHD. There was significant statistical difference of mortality rates between the mild group (5.5%) and the critical group (30.4%).The average time of hospitalization was 16.9 (9, 22) days. Hypertension MESHD was the most common comorbidity (n=90, 68.2%), followed by diabetes MESHD (n=45, 34.1%), coronary heart disease MESHD (31, 23.5%). Compared with the mild group, the patients were older in critical group (P <0.05), and neutrophils, neutrophil ratio, neutrophil-lymphocyte ratio (NLR), serum urea nitrogen (BUN), procalcitonin (PCT), C-reactive protein CRP), serum amyloid protein ( SSA HGNC), N-terminal brain natriuretic peptide precursor (NT-pro BNP) were significantly increased (P <0.05). However, lymphocytes lymphocyte ratio, albumin were lower than those in the critical group (P <0.05). The patients were further divided into the survivor group (n=119, 90.2%) and the non-survivor group (n=13, 9.8%). Compared with the survivor group, the death rate of patients with coronary heart disease MESHD was significantly increased (53.8% vs 20.2%), and The neutrophil ratio, aspartate aminotransferase ( AST HGNC), BUN, PCT, CRP HGNC, SAA, interleukin-6 HGNC( IL-6 HGNC) and D-dimer were significantly increased (P <0.05), while the lymphocytes and NLR reduced (P <0.05). Multivariate logistic stepwise regression analysis showed that the past medical history of coronary heart disease MESHD[OR:2.806 95%CI:0.971~16.795], decreased lymphocytes[OR:0.040, 95%CI:0.001~2.306], increased AST HGNC[OR:1.026, 95%CI:1.000~1.052], increased SSA HGNC[OR:1.021, 95%CI:1.001~1.025], and increased D-dimer[OR:1.231, 95%CI:1.042~1.456] are risk factors associated with death MESHD in COVID-19 MESHD patients pneumonia MESHD with comorbidities. Conclusion: The mortality rate of COVID-19 MESHD patients with coronary heart disease MESHD is relatively high. In all patients, the lower lymphocytes, and higher NLR, BUN, PCT, CRP HGNC, SSA HGNC, D-dimer are significant characteristics. The past medical history of coronary heart disease MESHD, decreased lymphocytes, increased AST HGNC, SSA HGNC and D-dimer are risk factors associated with death MESHD in COVID-19 MESHD pneumonia MESHD patients with comorbidities

    Risk factors and clinical features of deterioration in COVID-19 MESHD patients in Zhejiang, China: a single- centre, retrospective study

    Authors: Ping Yi; Xiang Yang; Cheng Ding; Yanfei Chen; Kaijin Xu; Qing Ni; Hong Zhao; Yongtao Li; Xuan Zhang; Jun Liu; Jifang Sheng; Lanjuan Li

    doi:10.21203/rs.3.rs-22481/v4 Date: 2020-04-11 Source: ResearchSquare

    BackgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection MESHD swept through Wuhan and spread across China and overseas beginning in December 2019. To identify predictors associated with disease progression, we evaluated clinical risk factors for exacerbation of SARS-CoV-2 infection MESHD.MethodsA retrospective analysis was used for PCR-confirmed COVID-19 MESHD ( coronavirus disease 2019 MESHD)-diagnosed hospitalized cases between January 19, 2020, and February 19, 2020, in Zhejiang, China. We systematically analysed the clinical characteristics of the patients and predictors of clinical deterioration.ResultsOne hundred patients with COVID-19 MESHD, with a median age of 54 years, were included. Among them, 49 patients (49%) had severe and critical disease MESHD. Age ([36-58] vs [51-70], P=0.0001); sex (49% vs 77.6%, P=0.0031); Body Mass Index (BMI ) ([21.53-25.51] vs [23.28-27.01], P=0.0339); hypertension MESHD (17.6% vs 57.1%, P<0.0001); IL-6 HGNC ([6.42-30.46] vs [16.2-81.71], P=0.0001); IL-10 HGNC ([2.16-5.82] vs [4.35-9.63], P<0.0001); T lymphocyte count ([305- 1178] vs [167.5-440], P=0.0001); B lymphocyte count ([91-213] vs [54.5-163.5], P=0.0001); white blood cell count ([3.9-7.6] vs [5.5-13.6], P=0.0002); D2 dimer ([172-836] vs [408-953], P=0.005), PCT ([0.03-0.07] vs [0.04-0.15], P=0.0039); CRP HGNC ([3.8-27.9] vs [17.3-58.9], P<0.0001); AST HGNC ([16, 29] vs [18, 42], P=0.0484); artificial liver therapy (2% vs 16.3%, P=0.0148); and glucocorticoid therapy (64.7% vs 98%, P<0.0001) were associated with the severity of the disease. Age and weight were independent risk factors for disease severity.ConclusionDeterioration among COVID-19 MESHD-infected patients occurred rapidly after hospital admission. In our cohort, we found that multiple factors were associated with the severity of COVID19 MESHD. Early detection and monitoring of these indicators may reduce the progression of the disease. Removing these factors may halt the progression of the disease. In addition, Oxygen support, early treatment with low doses of glucocorticoids and liver therapy, when necessary, may help reduce mortality in critically ill MESHD patients.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.